We are live on
!
Find out more
Loomis, Sayles & Company Portfolio holdings
AUM
$74.3B
1-Year Est. Return
24.01%
This Fund
S&P 500
This Quarter
Est. Return
+10.76%
1 Year Est. Return
+24.01%
3 Year Est. Return
+109.67%
5 Year Est. Return
+145.58%
10 Year Est. Return
+623.12%
AUM
$82.5B
AUM Growth
+$5.26B
(+6.8%)
Cap. Flow
-$2.02B
Cap. Flow
% of AUM
-2.45%
Top 10 Holdings %
Top 10 Hldgs %
38.94%
Holding
962
New
129
Increased
342
Reduced
292
Closed
136
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vertex Pharmaceuticals
VRTX
|
+$429M |
| 2 |
Airbnb
ABNB
|
+$235M |
| 3 |
T-Mobile US
TMUS
|
+$156M |
| 4 |
Alnylam Pharmaceuticals
ALNY
|
+$139M |
| 5 |
CRISPR Therapeutics
CRSP
|
+$111M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Deere & Co
DE
|
+$488M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$222M |
| 3 |
Expeditors International
EXPD
|
+$191M |
| 4 |
Qualcomm
QCOM
|
+$187M |
| 5 |
CERN
Cerner Corp
CERN
|
+$171M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.12% |
| 2 | Consumer Discretionary | 15.99% |
| 3 | Communication Services | 13.72% |
| 4 | Healthcare | 12.84% |
| 5 | Industrials | 11.68% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
426
JPMorgan Chase
JPM
$950B
| $2M | ﹤0.01% |
12,862
+8,139
| +172% | +$1.28M |
|
427
Thermo Fisher Scientific
TMO
$220B
| $2M | ﹤0.01% |
3,960
+389
| +11% | +$184K |
|
428
Citigroup
C
$226B
| $1.97M | ﹤0.01% |
27,855
+1,550
| +6% | +$115K |
|
429
Philip Morris
PM
$295B
| $1.97M | ﹤0.01% |
19,839
+1,107
| +6% | +$106K |
|
430
Caterpillar
CAT
$387B
| $1.96M | ﹤0.01% |
9,029
+8,916
| +7,890% | +$2.06M |
|
431
Allstate
ALL
$67.5B
| $1.91M | ﹤0.01% |
14,654
+4,507
| +44% | +$582K |
|
432
TJX Companies
TJX
$178B
| $1.91M | ﹤0.01% |
+28,269
| New | +$1.93M |
|
433
Lowe's Companies
LOW
$125B
| $1.87M | ﹤0.01% |
9,624
+826
| +9% | +$162K |
|
434
AES
AES
$10.5B
| $1.86M | ﹤0.01% |
+71,188
| New | +$1.88M |
|
435
Ross Stores
ROST
$81.9B
| $1.85M | ﹤0.01% |
14,900
+14,702
| +7,425% | +$1.83M |
|
436
HP
HPQ
$27.5B
| $1.84M | ﹤0.01% |
60,827
+60,484
| +17,634% | +$1.93M |
|
437
Ryder
R
$10.1B
| $1.82M | ﹤0.01% |
24,437
+582
| +2% | +$46K |
|
438
OneMain Financial
OMF
$7.47B
| $1.79M | ﹤0.01% |
+29,955
| New | +$1.7M |
|
|
NBIS
439
Nebius Group N.V.
NBIS
$47.7B
| $1.79M | ﹤0.01% |
25,365
-2,006
| -7% | -$132K |
|
440
ConocoPhillips
COP
$141B
| $1.79M | ﹤0.01% |
29,390
+28,991
| +7,266% | +$1.62M |
|
441
Lam Research
LRCX
$390B
| $1.78M | ﹤0.01% |
27,430
+500
| +2% | +$31.6K |
|
442
Pfizer
PFE
$153B
| $1.78M | ﹤0.01% |
45,440
+3,270
| +8% | +$127K |
|
443
Fidelity National Financial
FNF
$13.5B
| $1.77M | ﹤0.01% |
42,395
+39,703
| +1,475% | +$1.73M |
|
444
Tyson Foods
TSN
$20.4B
| $1.77M | ﹤0.01% |
23,993
+22,125
| +1,184% | +$1.72M |
|
445
LyondellBasell Industries
LYB
$19.2B
| $1.75M | ﹤0.01% |
16,999
+16,826
| +9,726% | +$1.82M |
|
446
Norfolk Southern
NSC
$75.1B
| $1.75M | ﹤0.01% |
6,586
+6,458
| +5,045% | +$1.78M |
|
|
IPG
447
DELISTED
Interpublic Group of Companies
IPG
| $1.74M | ﹤0.01% |
53,578
-3,577
| -6% | -$114K |
|
448
Parker-Hannifin
PH
$135B
| $1.74M | ﹤0.01% |
5,649
-313,796
| -98% | -$97.1M |
|
449
IBM
IBM
$224B
| $1.73M | ﹤0.01% |
12,372
+106
| +0.9% | +$14.5K |
|
450
Omega Healthcare
OHI
$14.7B
| $1.73M | ﹤0.01% |
47,766
+47,683
| +57,449% | +$1.77M |
|
Similar funds
CBU
BC
Loomis, Sayles & Company's Q2 2021 Portfolio in Review
As of Q2 2021, Loomis, Sayles & Company held 962 positions worth $82.5B, up 6.8% from $77.2B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Loomis, Sayles & Company's Q2 2021 filing shows 129 new, 342 increased, 292 reduced and 136 closed positions. Its largest new stake was Alnylam Pharmaceuticals: 946,065 shares worth $160M. The largest sale was Deere & Co, an estimated $488M.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 25% a quarter earlier, followed by Consumer Discretionary and Communication Services.
- Loomis, Sayles & Company's largest Q2 2021 buy was Alnylam Pharmaceuticals: 946,065 shares worth $160M.
- Loomis, Sayles & Company added most to Vertex Pharmaceuticals in Q2 2021, an estimated $429M increase.
- Loomis, Sayles & Company's biggest Q2 2021 reduction was Deere & Co, cutting an estimated $488M.
- Loomis, Sayles & Company fully exited Goosehead Insurance in Q2 2021, selling an estimated $66.6M.
- Loomis, Sayles & Company's ten largest holdings make up 39% of its $82.5B portfolio in Q2 2021.
- Loomis, Sayles & Company opened 129 new positions and closed 136 in Q2 2021.
- Loomis, Sayles & Company's portfolio value rose 6.8% quarter-over-quarter to $82.5B.
Based on Loomis, Sayles & Company's 13F filing for Q2 2021, filed 13 Aug 2021.